Phase III, Multicenter, Open-label, Randomized Trial of Tarceva (Rm) vs Chemotherapy in Patients With Advanced NSCLC With Mutations in the TK Domain of the EGFR

Trial Profile

Phase III, Multicenter, Open-label, Randomized Trial of Tarceva (Rm) vs Chemotherapy in Patients With Advanced NSCLC With Mutations in the TK Domain of the EGFR

Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Erlotinib (Primary) ; Carboplatin; Cisplatin; Docetaxel; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms EURTAC
  • Most Recent Events

    • 18 Oct 2017 Results assessing Overall survival Adjusting for Post-Progression Treatment Crossover in three phase III trials (EURTAC, ENSURE and OPTIMAL), presented at the 18th World Conference on Lung Cancer
    • 10 Jun 2017 Biomarkers information updated
    • 02 Jun 2015 Results from a meta-analysis of 6 trials showing impact on overall survival in patients with EGFR mutations presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top